This is the nature of bio- tech company, high risk and high reward at the same time, FDA approval is the key.

Orphazyme rose more than 6% in premarket trading

(June 21) Orphazyme rose more than 6% in premarket trading.  What happened Shares of Orphazyme, a c
Orphazyme rose more than 6% in premarket trading

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

  • Top
  • Latest
empty
No comments yet